نتایج جستجو برای: autoimmune thrombocytopenia

تعداد نتایج: 84689  

Journal: :Haematologica 2006
Wilma Barcellini Silvana Capalbo Rosa Maria Agostinelli Francesca Romana Mauro Achille Ambrosetti Rossella Calori Agostino Cortelezzi Luca Laurenti Enrico Maria Pogliani Paola Pedotti Vincenzo Liso Gabriella Girelli Franco Mandelli Alberto Zanella

The aim of this multicenter GIMEMA study was to correlate autoimmune complications (AIC) in B-cell chronic lymphocytic leukemia (B-CLL) with stage and therapy. Autoimmune hemolytic anemia (129/194 cases) and autoimmune thrombocytopenia (35/194 cases) were typically present in advanced and multi-treated disease. Age over the median, stage C and first and second line therapy were identified as in...

2012

Autoimmune diseases affect around 5% of the population but until recently, although the pathological features of these disorders could be described, there was little idea about the aetiology. Through the development of animal models and the identification of target genes some insight is being gained into the pathogenetic basis of these complex diseases. Blood disorders in which autoantibodies a...

2000
P. J. Kraulis E. A. Merritt M. E. P. Murphy

with EBV: polyreactive antibodies and CD5 B lymphocytes. Annu. Rev. Immunol. 7, 513–525 52 Kipps, T. and Carson, D.A. (1993) Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 81, 2475–2487 53 Diehl, L.F. and Ketchum, L.H. (1998) Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thr...

Journal: :Turkish journal of haematology : official journal of Turkish Society of Haematology 2000
C Canpolat S Culbert H Zietz K Hoots

This study was performed to determine whether there is any distinction to be made between single and multiple-lineage cytopenias particularly with regard to natural history and prognosis. From December 1989 to May 1994, five of 50 children (median age 7 years) with chronic immune cytopenias were diagnosed with multi-lineage immune- ediated cytopenias. Two patients presented with immune thromboc...

Journal: :Archives of disease in childhood. Fetal and neonatal edition 1995
D L Cohen T P Baglin

Correspondence to: Dr D L Cohen, Department of Paediatrics, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ. The use of electronic cell counters has led to the recognition that pregnancy is frequently associated with thrombocytopenia. As well as disorders that cause thrombocytopenia in the non-pregnant state, a reduction in the circulating platelet count may result from the pregnancy itse...

2014
Ibrahim Elebrashy Elham Yousief Aasem Saif

We report a case of Addison's disease presenting with recurrent deep venous thrombosis and thrombocytopenia and proved to have primary anti-phospholipid antibody syndrome. The case report highlights the shared autoimmune nature of both diseases.

Journal: :Saudi medical journal 2012
Fatin M Al-Sayes Salwa I Hindawi Ghazi A Damanhouri Samy M Attallah Fatima A Azaher Daad H Akbar

OBJECTIVE To evaluate the association between autoimmune thrombocytopenia with other autoimmune disorders, to show if they are different autoimmune diseases or one disease with different presentations at the same time, and to study the effect of treatment on platelet count in different thyroid condition. METHODS In this retrospective study, we included 141 patients with thrombocytopenic purpu...

Journal: :Blood 2003
Seng Song Andrew R Crow John Freedman Alan H Lazarus

Intravenous immunoglobulin (IVIG) is used to treat immune thrombocytopenia resulting from a variety of autoimmune and nonautoimmune diseases such as idiopathic thrombocytopenic purpura (ITP), heparin-induced thrombocytopenia, and posttransfusion purpura. IVIG is a limited resource and although considered safe, may nevertheless carry some risk of transferring disease. Its high cost makes monoclo...

2017
Clémentine Estève Maxime Samson Alexandre Guilhem Barbara Nicolas Vanessa Leguy-Seguin Sabine Berthier Bernard Bonnotte Sylvain Audia

Dapsone is recommended as a second line therapy in immune thrombocytopenia (ITP), but is underused because of its potential side effects. The medical charts of 42 ITP patients treated with dapsone (100 mg/day) were retrospectively reviewed in order to assess its efficacy and safety in daily clinical practice. The overall response rate was 54.8% (n = 22, with a complete response in 38.1%) with a...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید